Accredited Investors Inc. Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Accredited Investors Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,246 shares of the company’s stock after purchasing an additional 43 shares during the quarter. Accredited Investors Inc.’s holdings in Eli Lilly and Company were worth $2,506,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Kennedy Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 17.0% during the 4th quarter. Kennedy Capital Management LLC now owns 41,351 shares of the company’s stock valued at $31,923,000 after buying an additional 6,011 shares during the period. Treasurer of the State of North Carolina grew its holdings in shares of Eli Lilly and Company by 1.0% in the 4th quarter. Treasurer of the State of North Carolina now owns 386,386 shares of the company’s stock worth $298,290,000 after acquiring an additional 3,915 shares during the last quarter. Bank of Hawaii grew its stake in Eli Lilly and Company by 4.0% during the 4th quarter. Bank of Hawaii now owns 9,612 shares of the company’s stock valued at $7,420,000 after acquiring an additional 374 shares in the last quarter. Phoenix Financial Ltd. raised its position in Eli Lilly and Company by 12.4% during the fourth quarter. Phoenix Financial Ltd. now owns 19,037 shares of the company’s stock valued at $14,697,000 after acquiring an additional 2,096 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc. lifted its position in Eli Lilly and Company by 46.1% during the 4th quarter. Mountain Capital Investment Advisors Inc. now owns 371 shares of the company’s stock worth $269,000 after acquiring an additional 117 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price objective for the company from $892.00 to $888.00 in a report on Tuesday. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Finally, Wells Fargo & Company raised their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,017.67.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $751.61 on Thursday. The stock has a 50-day moving average of $840.79 and a 200 day moving average of $826.23. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock has a market capitalization of $712.65 billion, a price-to-earnings ratio of 64.19, a PEG ratio of 1.40 and a beta of 0.51. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.